Correlation of rabbit antithymocyte globulin serum levels and clinical outcomes in children who received hematopoietic stem cell transplantation from an alternative donor

We analyzed the correlation between rabbit ATG (rATG) serum levels and clinical outcomes in 37 children who received rATG at a total dose of 10 or 15 mg/kg during HSCT conditioning from an alternative donor. Fourteen patients had advanced malignant diseases, 13 had severe AA, and 10 had inherited disorders. Complete engraftment was achieved in all patients, and no rejection occurred. The cumulative incidence of grades II–IV acute GVHD and extensive chronic GVHD was 27% (95% CI, 12.5–39.6%) and 8.1% (95% CI, 0–23.1%), respectively. Multivariate analysis identified lower rATG levels at week 4 as an independent risk factor in the development of grades II–IV acute GVHD (p = 0.037). Serious infections were not observed in any patient following HSCT. No correlation was found between EBV reactivation and rATG levels at week 2 and week 4 after HSCT. Furthermore, no correlation was found between relapse and rATG levels two and four wk post‐transplantation. The probability of five‐yr OS among patients was 70.3% (95% CI, 59.8–79.2%). Our results suggest that targeted rATG administration may protect patients from severe acute GVHD without increasing the risk of EBV reactivation or relapse.

[1]  A. Bacigalupo.  How I treat acquired aplastic anemia. , 2017, Blood.

[2]  A. Webster,et al.  Post-transplant lymphoproliferative disorders , 2016, Nature Reviews Disease Primers.

[3]  M. Mohty,et al.  Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  M. Hosoya,et al.  T-cell-replete haploidentical stem cell transplantation is highly efficacious for relapsed and refractory childhood acute leukaemia , 2014, Transfusion medicine.

[5]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[6]  M. Remberger,et al.  Effects of different serum-levels of ATG after unrelated donor umbilical cord blood transplantation. , 2012, Transplant immunology.

[7]  M. Martelli,et al.  Haploidentical hematopoietic transplantation: current status and future perspectives. , 2011, Blood.

[8]  J Storek,et al.  High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts , 2011, Bone Marrow Transplantation.

[9]  J. Stoltz,et al.  The clinical value of concomitant Epstein Barr virus (EBV)-DNA load and specific immune reconstitution monitoring after allogeneic hematopoietic stem cell transplantation. , 2011, Transplant immunology.

[10]  H. Einsele,et al.  Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. , 2009, The Lancet. Oncology.

[11]  M. Remberger,et al.  Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  E. Jaffe,et al.  Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. , 2009, Blood.

[13]  Q. Jiang,et al.  Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  P. Bruzzi,et al.  Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  H. Deeg,et al.  Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  T. Klingebiel,et al.  Experiences with haploidentical stem cell transplantation in children with acute lymphoblastic leukemia. , 2005, Pathologie-biologie.

[17]  M. Remberger,et al.  Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. , 2005, Haematologica.

[18]  T. Klingebiel,et al.  Long-term outcome after haploidentical stem cell transplantation in children. , 2004, Blood cells, molecules & diseases.

[19]  S. Sakaguchi,et al.  CD4+ Tregs and immune control. , 2004, The Journal of clinical investigation.

[20]  M. Remberger,et al.  Dose Study of Thymoglobulin During Conditioning for Unrelated Donor Allogeneic Stem-Cell Transplantation , 2004, Transplantation.

[21]  D. Blaise,et al.  Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. , 2003, Blood.

[22]  T. Klingebiel,et al.  Megadose transplantation of highly purified haploidentical stem cells: current results and future prospects , 2003, Pediatric transplantation.

[23]  Y. Kodera,et al.  Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. , 2002, Blood.

[24]  P. Bruzzi,et al.  Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). , 2001, Blood.

[25]  K. Horibe,et al.  Prospective monitoring of the Epstein–Barr virus DNA by a real‐time quantitative polymerase chain reaction after allogenic stem cell transplantation , 2001, British journal of haematology.

[26]  T. Klingebiel,et al.  Megadose transplantation of purified peripheral blood CD34+progenitor cells from HLA-mismatched parental donors in children , 2001, Bone Marrow Transplantation.

[27]  A. Yoshimi,et al.  Long‐term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation , 2000, British journal of haematology.

[28]  D. Margolis,et al.  Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia. , 2000, Seminars in hematology.

[29]  E. Jaffe,et al.  Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. , 1999, Blood.

[30]  J. Hermans,et al.  Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. , 1996, Bone marrow transplantation.

[31]  D. M. Hamlin,et al.  COMPARATIVE POLYCLONAL ANTITHYMOCYTE GLOBULIN AND ANTILYMPHOCYTE/ANTILYMPHOBLAST GLOBULIN ANTI‐CD ANTIGEN ANALYSIS BY FLOW CYTOMETRY , 1995, Transplantation.

[32]  J. Thomas,et al.  A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. , 1994, Transplantation.

[33]  J. Hansen,et al.  Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. , 1993, The New England journal of medicine.

[34]  G. Heller,et al.  Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. , 1989, Blood.

[35]  E. Gluckman,et al.  Bone marrow transplantation for severe aplastic anemia from donors other than HLA identical siblings: a report of the BMT Working Party. , 1988, Bone marrow transplantation.

[36]  M. Zutter,et al.  Epstein-Barr virus lymphoproliferation after bone marrow transplantation. , 1988, Blood.